Free Trial
NASDAQ:TNYA

Tenaya Therapeutics (TNYA) Stock Price, News & Analysis

Tenaya Therapeutics logo
$1.24 +0.06 (+5.08%)
Closing price 04:00 PM Eastern
Extended Trading
$1.22 -0.02 (-2.02%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tenaya Therapeutics Stock (NASDAQ:TNYA)

Key Stats

Today's Range
$1.14
$1.26
50-Day Range
$0.58
$1.26
52-Week Range
$0.36
$4.01
Volume
4.51 million shs
Average Volume
2.96 million shs
Market Capitalization
$202.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25
Consensus Rating
Buy

Company Overview

Tenaya Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

TNYA MarketRank™: 

Tenaya Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 467th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tenaya Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Tenaya Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Tenaya Therapeutics are expected to grow in the coming year, from ($1.35) to ($1.26) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tenaya Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tenaya Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tenaya Therapeutics has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Tenaya Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.66% of the float of Tenaya Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tenaya Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Tenaya Therapeutics has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tenaya Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Tenaya Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.66% of the float of Tenaya Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tenaya Therapeutics has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Tenaya Therapeutics has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Tenaya Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Tenaya Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    36 people have searched for TNYA on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,185.00 in company stock.

  • Percentage Held by Insiders

    48.65% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tenaya Therapeutics' insider trading history.
Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TNYA Stock News Headlines

Trump’s national nightmare is here
The headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — and insiders say it’s just the start. According to two veteran analysts, this move isn’t about politics. It’s about urgency. The U.S. is mobilizing for what could be the most important economic war of the century: the race for AI dominance. And behind the scenes, a handful of little-known companies could be next in line for lucrative government deals.tc pixel
See More Headlines

TNYA Stock Analysis - Frequently Asked Questions

Tenaya Therapeutics' stock was trading at $1.43 on January 1st, 2025. Since then, TNYA shares have decreased by 13.3% and is now trading at $1.24.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06.

Tenaya Therapeutics (TNYA) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

Tenaya Therapeutics' top institutional investors include Geode Capital Management LLC (0.76%), Marex Group plc (0.25%), Jane Street Group LLC (0.23%) and Marshall Wace LLP (0.09%). Insiders that own company stock include Group Gp Lp Column III, David V Goeddel, Deepak Srivastava, Faraz Ali, Timothy Hoey, Whittemore Tingley, Tomohiro Higa and Chihiro Saito.
View institutional ownership trends
.

Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/06/2025
Today
9/04/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TNYA
CIK
1858848
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$5.00
Potential Upside/Downside
+427.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$111.13 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-93.83%
Return on Assets
-75.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.00
Quick Ratio
6.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
1.94

Miscellaneous

Outstanding Shares
162,980,000
Free Float
83,688,000
Market Cap
$193.13 million
Optionable
Optionable
Beta
3.07

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:TNYA) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners